Journal
VACCINE
Volume 20, Issue 15, Pages 1949-1955Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S0264-410X(02)00076-2
Keywords
mucosal challenged; multiprotein; heterologous prime; boost
Categories
Funding
- NCRR NIH HHS [P51 RR 00165] Funding Source: Medline
- NIAID NIH HHS [P01 AI 43045] Funding Source: Medline
- NIDA NIH HHS [P30 DA 12121] Funding Source: Medline
Ask authors/readers for more resources
Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here, we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a Rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic. (C) 2002 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available